## 옻나무(*Rhus verniciflua* Strokes) 주요 단일성분과 그 유도체를 이용한 다중기전 림프부종 치료제 후보물질 개발

이석찬<sup>1</sup>, <u>구진모</u><sup>2</sup>\*

<sup>1</sup>성균관대학교 생명공학대학 융합생명공학과, 교수, <sup>2</sup>경기도경제과학진흥원 바이오센터, 수석연구원

## Development of Drug Candidate for the Treatment of Lymphedema Using Natural Product and its Derivatives from *Rhus verniciflua* Strokes

## Sukchan Lee<sup>1</sup> and Jin-Mo Ku<sup>2</sup>\*

<sup>1</sup>Professor, Department of Integrative Biotechnology, Sungkyunkwan University, Korea <sup>2</sup>Principal Investigator, Bio-Center, Gyeonggido Business & Science Accelerator, Korea

Herein, we demonstrate that butein (1) can prevent swelling in a murine lymphedema model by suppressing tumor necrosis factor  $\alpha$  (TNF- $\alpha$ ) production. Butein derivatives were synthesized and evaluated to identify compounds with in vitro anti-inflammatory activity. Among them, 20  $\mu$ M of compounds **7j**, **7m**, and **14a** showed 50% suppression of TNF- $\alpha$  production in mouse peritoneal macrophages after lipopolysaccharide stimulation. Compound 14a, exhibited the strongest potency with an in vitro IC<sub>50</sub> of 14.6  $\mu$ M and suppressed limb volume by 70% in a murine lymphedema model. The prodrug strategy enabled a six-fold increase in kinetic solubility of compound **1** and five-fold higher levels of active metabolite in the blood for compound **14a** via oral administration in the pharmacokinetics study. We suggest that the compound **14a** could be developed as a potential therapeutic agent targeting anti-inflammatory activity to alleviate lymphedema progression.



[본 연구는 경기도, 국내외 천연물 및 합성 소재개발사업의 지원에 의해 이루어진 결과로 이에 감사드립니다.]

\*(Corresponding author) medichem@gbsa.or.kr, Tel: +82-31-888-6934